Smart-Money SignalNeutral · 52/100— Insider open-market flow is flat over 90 days
Revenue$495.0K
Net Income-$3.5M
EPS$-0.58
Gross Margin90.7%
Market Cap$20.2M
Price Performance
Historical data including institutional events
Company Profile
E
Eric Schlorff
CEO & Executive Director
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease.
SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
